SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Objects to Dendreon Corporation Promotions for Provenge

August 9, 2010 | 
1 min read
Reuters -- Dendreon Corp exaggerated the benefits of its novel prostate cancer vaccine and downplayed risks in some sales materials for the product, U.S. regulators said in a letter released on Friday.
Legal Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Megaphone with stethoscope isolated on orange background. 3d illustration
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage of gavel, safety cones and roadblock
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Regulatory
FDA Mulls ‘Regulatory Action’ on Argenx’s Vyvgart Hytrulo Over Severe Safety Concerns
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac